Categories: Market Research

Actinic Keratosis Treatment Market Size and Forecast 2024-2033|Sun Pharmaceutical Industries Ltd., Novartis AG, Hill Dermaceuticals Inc., Bausch Health Companies Inc., LEO Pharma A/S

Topical treatment with an antimetabolic for actinic keratosis leaves skin a blotchy mess during the treatment but shows vast improvement after treatment is done.

Overview and Scope

Actinic keratoses treatment refers to a treatment done for actinic keratoses, a skin disease that appears on the face, scalp, backs of the hands, or chest as a result of sun exposure. This treatment decreases the risk of developing the skin condition by keeping the skin protected from ultraviolet (UV) rays and limiting regular exposure to the sun.

Sizing and Forecast

The actinic keratosis treatment market size has grown strongly in recent years. It will grow from $3 billion in 2023 to $3.24 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to treatment adherence, market competition, patient education initiatives, dermatological practices, research and clinical trials.

The actinic keratosis treatment market size is expected to see strong growth in the next few years. It will grow to $4.36 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to patient education and engagement, digital health integration, growing awareness, focus on preventive dermatology, personalized medicine trends.. Major trends in the forecast period include shift towards combination therapies, technological advancements, personalized treatment approaches, increasing incidence rates, minimally invasive treatments.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/actinic-keratosis-treatment-global-market-report

Segmentation & Regional Insights

The actinic keratosis treatment market covered in this report is segmented –

1) By Treatment: Topical Treatment, Procedural Modality, Photodynamic Therapy, Other Treatments

2) By Medication: Flurouracil Cream, Imiquimod Cream, Ingenol Mebutate Gel, Diclofenac Gel

3) By End User: Hospitals, Private Dermatology Clinics, Laser Therapy Centers, Cancer Treatment Centers, Spas and Rejuvenation Centers, Homecare

North America was the largest region in the actinic keratosis treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regionscovered in the actinic keratosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8283&type=smp

Major Driver Impacting Market Growth

The growing prevalence of actinic keratosis is expected to propel the growth of the actinic keratosis treatment market going forward. An actinic keratosis refers to a rough, scaly area of skin that appears as a result of years of exposure to the sun. Actinic keratosis treatment helps to identify and treat precancerous lesions by reducing their risk. Growing actinic keratosis prevalence leads to increased demand for actinic keratosis treatment products, potential medications in research, and recommendations for the use of topical treatments. For instance, in February 2022, according to the article by World Cancer Research Fund International, a UK-based organization, there were more than 150,000 new cases of actinic keratosis in 2020, which increased to 197,700 cases in 2022. Therefore, the growing prevalence of actinic keratosis drives the actinic keratosis treatment market.

Key Industry Players

Major companies operating in the actinic keratosis treatment market report are Sun Pharmaceutical Industries Ltd., Novartis AG, Hill Dermaceuticals Inc., Bausch Health Companies Inc., LEO Pharma A/S, Almirall SA, Biofrontera AG, Galderma SA, Mylan NV, Cipher Pharmaceuticals Inc., Pierre Fabre Pharmaceuticals Inc., Tolmar Pharmaceuticals Inc., Stanford Chemicals Company, Glaxo Smith Kline plc, Alma Lasers Ltd., 3M Company, Nestle SA, Cutanea Life Sciences Inc., DUSA Pharmaceuticals Inc., Foamix Pharmaceuticals Ltd., G&W Laboratories Inc., Hikma Pharmaceuticals plc, Innocutis Holdings LLC, Mayne Pharma Group Limited, Meda AB, Merz Pharma GmbH & Co KGaA, Perrigo Company plc, PharmaDerm A division of Fougera Pharmaceuticals Inc., Promius Pharma LLC, Ranbaxy Laboratories Limited, Sandoz International GmbH, Stiefel Laboratories Inc., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International Inc., Zydus Pharmaceuticals Inc., Dermira Inc., Menlo Therapeutics Inc., Sol-Gel Technologies Ltd., Verrica Pharmaceuticals Inc.

The actinic keratosis treatment market report table of contents includes:

1. Executive Summary

2. Actinic Keratosis Treatment Market Characteristics

3. Actinic Keratosis Treatment Market Trends And Strategies

4. Actinic Keratosis Treatment Market – Macro Economic Scenario

5. Global Actinic Keratosis Treatment Market Size and Growth

26. South America Actinic Keratosis Treatment Market

27. Brazil Actinic Keratosis Treatment Market

28. Middle East Actinic Keratosis Treatment Market

29. Africa Actinic Keratosis Treatment Market

30. Actinic Keratosis Treatment Market Competitive Landscape And Company Profiles

Top Major Players: